Erratum: Real role of b-blockers in regression of left ventricular mass in hypertension patients: Bayesian network meta-analysis (Medicine (United States) 96:10 (e6290) DOI: 10.1097/MD.0000000000006290);Real role of β-blockers in regression of left ventricular mass in hypertension patients

Medicine (United States)

Volumn 96, Issue 10, 2017, Pages

  Xing, Fu Wei ^a   Chen, Jialin ^b   Zhao, Bin Liang ^a   Jiang, Jingzhou ^a   Tang, Anli ^a   Chen, Yili ^a  

^a THE FIRST AFFILIATED HOSPITAL OF SUN YAT SEN UNIVERSITY   (China)

^b SUN YAT SEN UNIVERSITY   (China)

Author keywords

anti hypertensive drug; Bayesian network analysis; hypertension; left ventricular hypertrophy; blockers

Indexed keywords

ANTIHYPERTENSIVE AGENT; ATENOLOL; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CALCIUM CHANNEL BLOCKING AGENT; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIURETIC AGENT; ENALAPRIL; EPROSARTAN; HYDROCHLOROTHIAZIDE; INDAPAMIDE; LISINOPRIL; METOPROLOL; NEBIVOLOL; NIMODIPINE; NITRENDIPINE; PERINDOPRIL; RAMIPRIL; TELMISARTAN;

BODY MASS; CELL HETEROGENEITY; COMPARATIVE STUDY; ECHOCARDIOGRAPHY; HEART LEFT VENTRICLE HYPERTROPHY; HEART LEFT VENTRICLE MASS; HUMAN; HYPERTENSION; META ANALYSIS; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; SYSTEMATIC REVIEW; TREATMENT DURATION; BAYES THEOREM; COMPLICATION; DRUG EFFECTS; HEART VENTRICLE; HYPERTROPHY, LEFT VENTRICULAR;

ADRENERGIC BETA-ANTAGONISTS; ANTIHYPERTENSIVE AGENTS; BAYES THEOREM; HEART VENTRICLES; HUMANS; HYPERTENSION; HYPERTROPHY, LEFT VENTRICULAR;

EID: 85015822587     PISSN: 00257974     EISSN: 15365964     Source Type: Journal    
DOI: 10.1097/MD.0000000000010991     Document Type: Erratum

References (43)

1. Bombelli M, Facchetti R, Carugo S, et al. Left ventricular hypertrophy increases cardiovascular risk independently of in-office and out-of-office blood pressure values. J Hypertens 2009;27:2458-64.
2. Mansia G, De Backer G, Dominiczak A, et al. 2007 ESH-ESC Guidelines for the management of arterial hypertension: the task force for the management of arterial hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC). Blood Pressur 2007;16:135-232.
3. Okin PM, Devereux RB, Jern S, et al. Regression of electrocardiographic left ventricular hypertrophy during antihypertensive treatment and the prediction of major cardiovascular events. JAMA 2004;292:2343-9.
4. Okin PM, Gerdts E, Wachtell K, et al. Relationship of left atrial enlargement to persistence or development of ECG left ventricular hypertrophy in hypertensive patients: implications for the development of new atrial fibrillation. J Hypertens 2010;28:1534-40.
5. de Simone G, Gottdiener JS, Chinali M, et al. Left ventricular mass predicts heart failure not related to previous myocardial infarction: the Cardiovascular Health Study. Eur Heart J 2008;29:741-7.
6. Schmieder RE, Kjeldsen SE, Julius S, et al. Reduced incidence of newonset atrial fibrillation with angiotensin II receptor blockade: the VALUE trial. J Hypertens 2008;26:403-11.
7. Fagard RH, Celis H, Thijs H, et al. Regression of left ventricular mass by antihypertensive treatment a meta-analysis of randomized comparative studies. Hypertension 2009;54:1084-91.
8. Klingbeil AU, Schneider M, Martus P, et al. A meta-analysis of the effects of treatment on left ventricular mass in essential hypertension. Am JMed 2003;115:41-6.
9. Schmieder RE, Martus P, Klingbeil A. Reversal of left ventricular hypertrophy in essential hypertension. A meta-analysis of randomized double-blind studies. JAMA 1996;275:1507-13.
10. Aronow WS, Fleg JL, Pepine CJ, et al. ACCF/AHA 2011 expert consensus document on hypertension in the elderly: a report of the American College of Cardiology Foundation Task Force on Clinical Expert Consensus Documents developed in collaboration with the American Academy of Neurology, American Geriatrics Society, American Society for Preventive Cardiology, American Society of Hypertension, American Society of Nephrology, Association of Black Cardiologists, and European Society of Hypertension. J Am Soc Hypertens 2011;5:259-352.
11. Ca Lar N, Dincer I. Comparison between nebivolol and ramipril in patients with hypertension and left ventricular hypertrophy: a randomized open blinded end-point (PROBE) trial. Eur Rev Med Pharmacol Sci 2011;15:1359.
12. Thompson SG, Higgins JP. How should meta-regression analyses be undertaken and interpreted? Stat Med 2002;21:1559-73.
13. Moher D, Liberati A, Tetzlaff J, et al. Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. Int J Surg 2010;8:336-41.
14. Dias S, Sutton AJ, Ades AE, et al. Evidence synthesis for decision making 2: a generalized linear modeling framework for pairwise and network meta-analysis of randomized controlled trials. Medical Decis Making 2013;33:607-17.
15. Rudroju N, Bansal D, Talakokkula ST, et al. Comparative efficacy and safety of six antidepressants and anticonvulsants in painful diabetic neuropathy: a network meta-analysis. Pain Physician 2013;16: E705-14.
16. Wang W, You L, Chiang C, et al. Comparative effectiveness of blood pressure-lowering drugs in patients who have already suffered from stroke. Medicine 2016;95:e3302.
17. Ades AE, Sculpher M, Sutton A, et al. Bayesian methods for evidence synthesis in cost-effectiveness analysis. Pharmacoeconomics 2006; 24:1-9.
18. Salanti G, Ades AE, Ioannidis JPA. Graphical methods and numerical summaries for presenting results from multiple-treatment meta-analysis: an overview and tutorial. J Clin Epidemiol 2011;64:163-71.
19. Santulli G. Adrenal signaling in heart failure: something more than a distant ship's smoke on the horizon. Hypertension 2014;63:215-6.
20. Sorriento D, Santulli G, Fusco A, et al. Intracardiac injection of AdGRK5-NT reduces left ventricular hypertrophy by inhibiting NF-Bdependent hypertrophic gene expression. Hypertension 2010;56: 696-704.
21. Sorriento D, Ciccarelli M, Santulli G, et al. The G-protein-coupled receptor kinase 5 inhibits NFkappaB transcriptional activity by inducing nuclear accumulation of IkappaB alpha. Proc Natl Acad Sci U S A 2008;105:17818-23.
22. Maung-U K. Pathophysiology and Pharmacotherapy of Cardiovascular Disease; 2017.
23. Kukin ML. Beta-blockers in chronic heart failure: considerations for selecting an agent. Mayo Clinic Proc 2002;77:1199-206.
24. Bisognano JD, Weinberger HD, Bohlmeyer TJ, et al. Myocardialdirected overexpression of the human beta(1)-adrenergic receptor in transgenic mice. J Mol Cell Cardiol 2000;32:817-30.
25. Engelhardt S, Hein L, Wiesmann F, et al. Progressive hypertrophy and heart failure in beta1-adrenergic receptor transgenic mice. Proc Natl Acad Sci U S A 1999;96:7059-64.
26. Milano CA, Allen LF, Rockman HA, et al. Enhanced myocardial function in transgenic mice overexpressing the beta 2-adrenergic receptor. Science (NY) 1994;264:582-6.
27. Liggett SB, Tepe NM, Lorenz JN, et al. Early and delayed consequences of beta(2)-adrenergic receptor overexpression in mouse hearts: critical role for expression level. Circulation 2000;101:1707-14.
28. Toblli J, Cao G, Rivas C, et al. Cardiovascular protective effects of nebivolol in Zucker diabetic fatty rats. J Hypertens 2010;28:1007-19.
29. Wolf SC, Sauter G, Preyer M, et al. Influence of nebivolol and metoprolol on inflammatory mediators in human coronary endothelial or smooth muscle cells. Effects on neointima formation after balloon denudation in carotid arteries of rats treated with nebivolol. Cell Physiol Biochem 2007;19:129-36.
30. Ignarro LJ, Sisodia M, Trinh K, et al. Nebivolol inhibits vascular smooth muscle cell proliferation by mechanisms involving nitric oxide but not cyclic GMP. Nitric Oxide 2002;7:83-90.
31. Andre DE, Arnet U, Yang Z, et al. Nebivolol inhibits human aortic smooth muscle cell growth: effects on cell cycle regulatory proteins. J Cardiovasc Pharmacol 2000;35:845-8.
32. Pires MJ, Rodriguez-Pena AB, Arevalo M, et al. Long-term nebivolol administration reduces renal fibrosis and prevents endothelial dysfunction in rats with hypertension induced by renal mass reduction. J Hypertens 2007;25:2486-96.
33. Maffei A, Di Pardo A, Carangi R, et al. Nebivolol induces nitric oxide release in the heart through inducible nitric oxide synthase activation. Hypertension 2007;50:652-6.
34. Galderisi M, D'Errico A, SidiropulosM, et al. Nebivolol induces parallel improvement of left ventricular filling pressure and coronary flow reserve in uncomplicated arterial hypertension. J Hypertens 2009;27:2108-15.
35. Brehm BR, Wolf SC, Bertsch D, et al. Effects of nebivolol on proliferation and apoptosis of human coronary artery smooth muscle and endothelial cells. Cardiovasc Res 2001;49:430-9.
36. Cuspidi C, Ciulla M, Zanchetti A. Hypertensive myocardial fibrosis. Nephrol Dial Transplant 2006;21:20-3.
37. Ciulla M, Paliotti R, Hess DB, et al. Echocardiographic patterns of myocardial fibrosis in hypertensive patients: endomyocardial biopsy versus ultrasonic tissue characterization. J Am Soc Echocardiogr 1997;10:657-64.
38. Dhakam Z, Yasmin ,McEniery CM, et al. A comparison of atenolol and nebivolol in isolated systolic hypertension. J Hypertens 2008;26:351-6.
39. McEniery CM, Schmitt M, Qasem A, et al. Nebivolol increases arterial distensibility in vivo. Hypertension 2004;44:305-10.
40. Roman MJ, Okin PM, Kizer RJ, et al. Relations of central and brachial blood pressure to left ventricular hypertrophy and geometry: the Strong Heart Study. J Hypertens 2010;28:384-8.
41. Van Bortel LM, Fici FF,Mascagni F. Efficacy and tolerability of nebivolol compared with other antihypertensive drugs: a meta-analysis. Am J Cardiovasc Drugs 2008;8:35-44.
42. Iwashima Y, Horio T, Kamide K, et al. Additive interaction of metabolic syndrome and chronic kidney disease on cardiac hypertrophy, and risk of cardiovascular disease in hypertension. Am J Hypertens 2010;23:290-8.
43. Tsunoda S, Kawano Y, Horio T, et al. Relationship between home blood pressure and longitudinal changes in target organ damage in treated hypertensive patients. Hypertens Res 2002;25:167-73.